A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo

Yonghyo Kim, Hye Jin Jung, Ho Jeong Kwon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.

Original languageEnglish
Pages (from-to)330-334
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume417
Issue number1
DOIs
Publication statusPublished - 2012 Jan 6

Fingerprint

Molecules
Voacanga
Vascular Endothelial Growth Factor A
Chorioallantoic Membrane
Hypoxia-Inducible Factor 1
Blood vessels
Blood Vessels
Tumors
Neoplasms
Genes
In Vitro Techniques
voacangine
Neoplasm Metastasis
Membranes
Phenotype
Growth

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

@article{2919588759274ff8be524d744d44b634,
title = "A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo",
abstract = "Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.",
author = "Yonghyo Kim and Jung, {Hye Jin} and Kwon, {Ho Jeong}",
year = "2012",
month = "1",
day = "6",
doi = "10.1016/j.bbrc.2011.11.109",
language = "English",
volume = "417",
pages = "330--334",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo. / Kim, Yonghyo; Jung, Hye Jin; Kwon, Ho Jeong.

In: Biochemical and Biophysical Research Communications, Vol. 417, No. 1, 06.01.2012, p. 330-334.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo

AU - Kim, Yonghyo

AU - Jung, Hye Jin

AU - Kwon, Ho Jeong

PY - 2012/1/6

Y1 - 2012/1/6

N2 - Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.

AB - Angiogenesis, the formation of new blood vessels from pre-existing ones, plays a critical role in normal and pathological phenotypes, including solid tumor growth and metastasis. Accordingly, the development of new anti-angiogenic agents is considered an efficient strategy for the treatment of cancer and other human diseases linked with angiogenesis. We have identified voacangine, isolated from Voacanga africana, as a novel anti-angiogenic agent. Voacangine inhibits the proliferation of HUVECs at an IC 50 of 18μM with no cytotoxic effects. Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion. Moreover, the compound inhibits in vivo angiogenesis in the chorioallantoic membrane at non-toxic doses. In addition, voacangine decreased the expression levels of hypoxia inducible factor-1α and its target gene, VEGF, in a dose-dependent manner. Taken together, these results suggest that the naturally occurring compound, voacangine, is a novel anti-angiogenic compound.

UR - http://www.scopus.com/inward/record.url?scp=84855821639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855821639&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2011.11.109

DO - 10.1016/j.bbrc.2011.11.109

M3 - Article

VL - 417

SP - 330

EP - 334

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -